MD Anderson Delta-Like Ligand 3 (DLL3) is a promising target in small cell lung cancer Leading Edge of Cancer Research Symposium
Median duration of response: 13 months
Tarlatamab - Bi- specific T cell engager (BiTE®) (NCT03392064)
BorghaeiH, WCLC 2022
MD Anderson DLL3 is highly expressed in neuroendocrine subtypes of SCLC Leading Edge of Cancer Research Symposium
DLL3 gene expression in SCLC patient samples
N P I A
N
P
I
A
SCLC subtypes
DLL3 surface expression DLL3 surface expression in SCLC by subtypes
0 20 40 60 80 100
A N P I Subtype
LixiaDiao Yan Yang
Cell line
Gay et al. Cancer Cell 2021
MD Anderson DLL3-targeting CAR T showed robust in-vitro cytotoxicity against SCLC Leading Edge of Cancer Research Symposium
H841
H82 DLL3 high
DLL3 low
0 20 40 60 80 100
0 20 40 60 80 100
DLL3 CAR T in vitro activity (E:T 1:1)
100
A
N P I
DLL3-CAR T
0
Cytotoxicity
Yan Yang
Page 1 Page 2 Page 3Made with FlippingBook interactive PDF creator